By Sabela Ojea
Shares of Xeris Biopharma climbed after the company guided for higher revenue in 2025.
The stock was up 17%, to $4.41, in Thursday trading, which is equivalent to the highest close since June 28, 2021. Shares have plunged 81% over the past 12 months.
The biopharmaceutical company projected full-year revenue of $255 million to $275 million, representing growth of over 30% at the mid-point range.
The Chicago company also expects adjusted earnings before interest, taxes, depreciation and amortization to remain positive going forward, Finance Chief Steven Pieper said.
"Our accelerating revenue growth, coupled with our attractive and improving margin profile and disciplined capital allocation, will result in a financially transformative 2025 for Xeris," Pieper said.
The company's outlook came as it reported a significant increase in product revenue in the fourth quarter.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
March 06, 2025 12:10 ET (17:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。